Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics
FATE-NK100 is a donor-derived natural killer (NK) cell product made of ex vivo activated effector cells with enhanced anti-tumor activity. It is studied in advanced solid tumors, including gastric, colorectal, lung, breast, liver, kidney, pancreatic and skin cancers, and head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03319459 | Phase 1 | HER2 Positive Gastric Cancer | Completed | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsColorectal CancerEGFR Positive Solid TumorHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaHER2 Positive Gastric CancerHER2-positive Breast CancerMelanomaNon Small Cell Lung CancerPancreatic CancerRenal Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →